Design of phase II cancer trials for evaluation of cytostatic/cytotoxic agents

Journal of Biopharmaceutical Statistics

Volumn 19, Issue 3, 2009, Pages 524-529

  Kocherginsky, Masha ^a   Cohen, Ezra E W ^a   Karrison, Theodore ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Multinomial response; Phase II clinical trial design; Stable disease

Indexed keywords

CYTOSTATIC AGENT; CYTOTOXIC AGENT; ENZASTAURIN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE;

ALGORITHM; ALTERNATIVE HYPOTHESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG SCREENING; HEAD AND NECK CANCER; METHODOLOGY; NULL HYPOTHESIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STANDARD; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION; HEAD AND NECK TUMOR; HUMAN; STATISTICS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; INDOLES; RESEARCH DESIGN;

EID: 67651046105     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400902802441     Document Type: Article

References (8)

1. Dent, S., Zee, B., Dancey, J., Hanauske, A., Wanders, J., Eisenhauer, E. (2001). Application of a new multinomial Phase II stopping rule using response and early progression. J. Clin. Oncol. 19:785-791.
2. Fleming, T. R. (1982). One sample multiple testing procedure for Phase II clinical trials. Biometrics 38:143-151.
3. Freidlin, B., Dancey, J., Korn, E. L., Zee, B., Eisenhauer, E. (2002). Multinomial Phase II trial designs (correspondence). J. Clin. Oncol. 20:599.
4. Karrison, T. G., Maitland, M. L., Stadler, W. M., Ratain, M. J. (2007). Design of Phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer. J. Natl. Cancer Inst. 99:1455-1461.
5. Lin, S. P., Chen, T. T. (2003). Multiple-stage designs for phase II cancer trials. In: Encyclopedia of Biopharmaceutical Statistics. New York: Marcel Dekker, Inc.
6. Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10:1-10.
7. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., Van Oosterom, A. T., Christian, M. C., Gwyther, S. G. (2000). New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92:205-216. (Pubitemid 30099779)
8. Zee, B., Melnychuk, D., Dancey, J., Eisenhauer, E. (1999). Multinomial phase II cancer trials incorporating response and early progression. J. Biopharmaceutical Statistics 9:351-363.